- Home
- CATO vs GNTA Comparison
CATO vs GNTA Comparison
Compare CATO & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CATO | GNTA |
|---|---|---|
| Founded | 1946 | 2014 |
| Country | United States | Italy |
| Employees | 7000 | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.5M | 39.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CATO | GNTA |
|---|---|---|
| Price | $3.44 | $1.86 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 55.7K | ★ 111.6K |
| Earning Date | 11-20-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $660,062,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.19 | $1.35 |
| 52 Week High | $4.92 | $10.00 |
Technical Indicators
Market Signals| Indicator | CATO | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 43.42 | 39.80 |
| Support Level | $3.35 | $1.80 |
| Resistance Level | $3.60 | $2.07 |
| Average True Range (ATR) | 0.17 | 0.23 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 63.16 | 57.65 |
Price Performance
Historical ComparisonAbout CATO Cato Corporation (The)
The Cato Corp operates as a specialty retailer of fashion apparel and accessories in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.